Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Sulforidazine

From Wikipedia, the free encyclopedia
Typical antipsychotic medication

Pharmaceutical compound
Sulforidazine
Clinical data
ATC code
  • none
Identifiers
  • 10-{2-[(RS)-1-Methylpiperidin-2-yl]ethyl}-2-(methylsulfonyl)-10H-phenothiazine
CAS Number
PubChemCID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.035.274Edit this at Wikidata
Chemical and physical data
FormulaC21H26N2O2S2
Molar mass402.57 g·mol−1
3D model (JSmol)
  • O=S(=O)(c2cc1N(c3c(Sc1cc2)cccc3)CCC4N(C)CCCC4)C
  • InChI=1S/C21H26N2O2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)26-21-11-10-17(15-19(21)23)27(2,24)25/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3 checkY
  • Key:FLGCRGJDQJIJAW-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Sulforidazine (Imagotan,Psychoson,Inofal) atypical antipsychotic and ametabolite ofthioridazine; it andmesoridazine are more potent than the parent compound, whose pharmacological effects are believed by some to be largely due to its metabolism into sulforidazine and mesoridazine.[1]

Synthesis

[edit]
Synthesis of sulforidazine

Sulforidazine can be synthesized starting 2-bromo-2'-amino-4'-methylsulfonyl-diphenyl sulfide (1).[2][3][4] Acetylation produces 2-bromo-2'-acetamino-4'-methylsulphonyl diphenylsulfide (2), which is then alkylated with 2-(2-chloroethyl)-1-methylpiperidine (3). Deacylation followed by a copper-catalyzed ring-formation reaction produces sulforidazine.

References

[edit]
  1. ^Niedzwiecki DM, Mailman RB, Cubeddu LX (March 1984). "Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors".The Journal of Pharmacology and Experimental Therapeutics.228 (3):636–639.doi:10.1016/S0022-3565(25)21884-5.PMID 6707914.
  2. ^"Sulforidazine".Thieme Pharmaceutical Substances.
  3. ^Morrow RJ, Millership JS, Collier PS (2005). "Facile Syntheses of the Three Major Metabolites of Thioridazine".Helvetica Chimica Acta.88 (5):962–967.Bibcode:2005HChAc..88..962M.doi:10.1002/hlca.200590089.
  4. ^US 3314948, Bruschweiler C, Schwarb G, Winkler H, Renz J, "Heterocyclic compounds", issued 18 April 1967, assigned to Sandoz AG. 
Typical
Disputed
Atypical
Others
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(andprodrugs)
nAChRsTooltip Nicotinic acetylcholine receptors
Agonists
(andPAMsTooltip positive allosteric modulators)
Antagonists
(andNAMsTooltip negative allosteric modulators)
Precursors
(andprodrugs)
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
H1
Agonists
Antagonists
H2
Agonists
Antagonists
H3
Agonists
Antagonists
H4
Agonists
Antagonists
Classes
Antidepressants
(Tricyclic antidepressants(TCAs))
Antihistamines
Antipsychotics
Anticonvulsants
Anticholinergics
Others
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sulforidazine&oldid=1311014763"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp